SOCMA Voices Concern over Chemical-Site Security Bill - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Voices Concern over Chemical-Site Security Bill


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) expressed “strong concern” over legislation introduced in the US Senate earlier this month regarding chemical-site security. The bill, the Secure Chemical Facilities Act (S 3599), was introduced by Sen. Frank Lautenberg (D-NJ).

SOCMA supports existing standards for chemical facilities being implemented by the US Department of Homeland Security (DHS) through the Chemical Facility Anti-Terrorism Act (CFATS). CFATS are risk-based performance standards for the security of US chemical facilities. Although the fine-chemical and chemical industries support the CFATS program, they oppose mandating the use of inherently safer technology (IST). IST is a conceptual framework that covers chemical processing procedures, equipment, protection, and when feasible, the use of safer substances.

SOCMA noted that DHS Secretary Janet Napolitano, who provided the keynote address at the 2010 Chemical Sector Security Summit earlier his month, voiced support for the CFATS measures. “Flexible, practical, and collaborative programs such as DHS' National Infrastructure Protection Plan, the Chemical Sector Coordinating Council, and Chemical Facility Anti-Terrorism Standards (CFATS), play a key role in enhancing the security and resiliency of our nation’s chemical facilities and other critical infrastructure," she said in a DHS statement.

SOCMA contends that the recently introduced Secure Chemical Facilities Act is not aligned with those measures. “Senator Lautenberg’s bill runs counter to the Secretary’s emphasis on a balanced approach to the existing CFATS program,” said SOCMA President and CEO Lawrence D. Sloan. “SOCMA appreciates the bill’s attention to the impact of its controversial provision, better known as inherently safer technology (IST), on small chemical facilities. However, IST is obviously not a common-sense mandate.”

The Lautenberg bill requires plants to assess their vulnerability and develop plans to address those vulnerabilities and requires the highest-risk facilities to put in place IST provisions. “When companies use chemicals that put thousands of lives at risk, it is essential that they find safer ways to do business,” said Lautenberg in a statement. “This is common-sense legislation that would ensure a thorough review of risk and help us move toward more secure plants and safer communities.”             

SOCMA said, “the legislation is majorly flawed because it mandates implementation of a process safety concept—not a security measure—a clear definition of which cannot be agreed upon by experts and which cannot be measured,” according to the SOCMA press release. “Academia and industry experts alike have repeatedly testified against mandating IST, yet this bill ignores those warnings.”

Instead, SOCMA is supporting the Senate bill, S. 2996, which extends the CFATS provisions.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here